Antidepressant Controlled Trial for Negative Symptoms in Schizophrenia

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

62 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-07-31

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this double-blind, placebo-controlled trial is to establish the clinical and cost effectiveness of an SSRI antidepressant, citalopram, in the management of persistent negative symptoms of schizophrenia over a year.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia

NCT01300364

Schizophrenia

UNKNOWN PHASE4

Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms

NCT01919216

Major Depressive Disorder

COMPLETED PHASE4

Functional MRI Evaluation of the Effect of Citalopram in Autism Spectrum Disorders

NCT00609531

Autism Spectrum Disorders

COMPLETED PHASE1

Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder

NCT01912391

Borderline Personality Disorder

COMPLETED PHASE3

TC-5214 as add-on the Treatment of Major Depressive Disorder

NCT00692445

Major Depressive Disorder Depression

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The negative symptoms of schizophrenia represent an important dimension of psychopathology, and reflect the absence or diminution of normal behaviours and functions. They include deficiencies in emotional responsiveness, drive, and emotional and social engagement. Persistent negative symptoms are held to account for much of the long-term morbidity and poor functional outcome in patients with established schizophrenia, but if they prove resistant to antipsychotic medication there is a very limited evidence base regarding specific treatments. The aim of this double-blind, placebo-controlled trial is to establish the clinical and cost effectiveness of an SSRI antidepressant, citalopram, in the management of negative symptoms of schizophrenia over a year. The study sample will be adults with a diagnosis of schizophrenia, clinically stable for 3 months with a consistent antipsychotic regimen, and characterised by persistent negative symptoms to a criterion level of severity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Citalopram

An SSRI antidepressant

Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* An OPCRIT (Operational Criteria Checklist for Psychosis: 57) diagnosis of schizophrenia, schizophreniform, schizoaffective disorder or psychosis NOS as defined by DSM-IV.
* A negative subscale score of 20 or more on the Positive and Negative Syndrome Scale for Schizophrenia (PANSS). At least three of the seven items on the negative symptom subscale should be rated 3 or more.
* Age 18-75 years, inclusive
* Clinically stable for the last 3 months with a consistent antipsychotic regimen.
* Competent and willing to provide written, informed consent.

Exclusion Criteria

* Any medical contraindications to an SSRI antidepressant.
* Currently receiving antidepressant or clinician wants to treat with an antidepressant;
* Taking any medications that risk interacting with citalopram
* Known congenital long QT syndrome, congestive heart failure, bradyarrhythmias
* QT limit above the upper limit of normal as determined by an electrocardiogram (ECG)
* Serum potassium and/or magnesium levels below the lower limits of normal
* Currently fulfil criteria for major depressive disorder; alcohol/substance hazardous use or dependence in past 3 months
* Treated with ECT in the last 8 weeks.
* Pregnant or planning to become pregnant
* Cognitive or language difficulties that would preclude subjects providing informed consent or compromise participation in study procedures.
* Lack of consent, as judged by the patient's psychiatrist

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No